Phase 2 Study May Be Added to Ongoing Trial of Combo Ovarian Cancer Immunotherapy

Phase 2 Study May Be Added to Ongoing Trial of Combo Ovarian Cancer Immunotherapy
Immunovaccine and Incyte Corporation are expanding their collaboration on a clinical trial, and plan to add a Phase 2 to their ongoing Phase 1b study in advanced ovarian cancer. The open-label Phase 1b trial (NCT02785250) is evaluating the safety and efficacy of Immunovaccine’s lead candidate DPX-Survivac in combination with Incyte’s IDO1 enzyme inhibitor epacadostat and

Knowledge is power when living with ovarian cancer.

Get access to the web’s leading Ovarian Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *